Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | YAP1 | P46937 | 1/20 | 0.49 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1265953 | 1.00 | KMT2A (1.00) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL1266612 | 0.85 | KMT2A (0.74) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL1266614 | 0.85 | KMT2A (0.74) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL1266159 | 0.84 | KMT2A (0.71) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL1266158 | 0.84 | KMT2A (0.71) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL3281358 | 0.83 | MEN1 (0.70) | KMT2AMEN1TSHRALDH1A1YAP1 | |
| SCHEMBL1266610 | 0.81 | KMT2A (0.68) | KMT2AMEN1TSHRLMNAMAPT | |
| SCHEMBL1266609 | 0.81 | KMT2A (0.68) | KMT2AMEN1TSHRLMNAMAPT | |
| SCHEMBL1265962 | 0.80 | KMT2A (0.67) | KMT2AMEN1TSHRALDH1A1LMNA | |
| SCHEMBL1265963 | 0.80 | KMT2A (0.67) | KMT2AMEN1TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951674-B1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | MERCK SERONO SA (CH) | 2011-11-23 | — | — | EP | disclosed |
| US-7879876-B2 | matrix metalloproteinase inhibitors such as N-{1-[(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)methyl]-3-phenylpropyl}-N-hydroxy formamide; prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular disorders, neurodegenerative diseases, cancer, respiratory system disorders and fibrosis | MERCK SERONO SA (CH) | 2011-02-01 | — | — | US | disclosed |
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | LABORATOIRES SERONO SA (CH) | 2009-09-03 | — | — | US | disclosed |
| EP-1951674-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | LABORATOIRES SERONO S.A. (CH) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007048788-A1 | SULFONAMIDE DERIVATIVES AND USE THEREOF FOR THE MODULATION OF METALLOPROTEINASES | LABORATOIRES SERONO S.A. (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221575-A1 | Sulfonamide derivatives and use thereof for the modulation of metalloproteinases | MMP12, STS, MMP14 | KMT2A 1261/4885MEN1 3388/4885TSHR 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.